BackgroundAs a rare subtype of primary lung adenocarcinoma (LUAD), mucinous pulmonary adenocarcinoma (MPA) was considered a distinctive entity with unfavorable outcomes. Therefore, there is a great need for a better understanding of the genomic and immunological landscape of this rare tumor type, which would inform improved therapeutic strategies.MethodsA total of 96 patients histologically confirmed with MPA were recruited from Shandong Cancer Hospital and Institute (SCH). Single nucleotide variation (SNV), copy number variation (CNV), genomic instability, and immunological landscape insights into 96 MPA patients were identified using WES.ResultsWe demonstrated that MPAs had marked different genomic alterations and were more complex in gen...
EGFR-mutant lung adenocarcinomas (LUAD) display diverse clinical trajectories and are characterized ...
Background: Lung adenocarcinoma (LUAD) is the most common histologic subtype of lung cancer and has ...
PURPOSE: To better understand the complete genomic architecture of lung adenocarcinoma. EXPERIMENTAL...
BackgroundAs a rare subtype of primary lung adenocarcinoma (LUAD), mucinous pulmonary adenocarcinoma...
BackgroundAs a rare subtype of primary lung adenocarcinoma (LUAD), mucinous pulmonary adenocarcinoma...
BackgroundAs a rare subtype of primary lung adenocarcinoma (LUAD), mucinous pulmonary adenocarcinoma...
Lung cancer is still the leading cause of cancer-related death worldwide. Of lung cancer, lung adeno...
Lung adenocarcinoma (LUAD) is the most common histologic subtype of lung cancer and has a high risk ...
INTRODUCTION: Invasive mucinous adenocarcinoma is a unique histologic subtype of lung cancer, and ou...
With the development of technologies, multiple primary lung cancer (MPLC) has been detected more fre...
Summary: Lung adenocarcinoma (LUAD) patients in East Asia predominantly harbor oncogenic EGFR mutati...
With the development of technologies, multiple primary lung cancer (MPLC) has been detected more fre...
Pulmonary invasive mucinous adenocarcinoma (IMA) is considered a variant of lung adenocarcinomas bas...
Background/Aims: Recurrent gene mutation has been identified by the analysis of exonic DNA from lung...
Invasive mucinous adenocarcinoma (IMA) of the lung frequently presents with diffuse pneumonic-type f...
EGFR-mutant lung adenocarcinomas (LUAD) display diverse clinical trajectories and are characterized ...
Background: Lung adenocarcinoma (LUAD) is the most common histologic subtype of lung cancer and has ...
PURPOSE: To better understand the complete genomic architecture of lung adenocarcinoma. EXPERIMENTAL...
BackgroundAs a rare subtype of primary lung adenocarcinoma (LUAD), mucinous pulmonary adenocarcinoma...
BackgroundAs a rare subtype of primary lung adenocarcinoma (LUAD), mucinous pulmonary adenocarcinoma...
BackgroundAs a rare subtype of primary lung adenocarcinoma (LUAD), mucinous pulmonary adenocarcinoma...
Lung cancer is still the leading cause of cancer-related death worldwide. Of lung cancer, lung adeno...
Lung adenocarcinoma (LUAD) is the most common histologic subtype of lung cancer and has a high risk ...
INTRODUCTION: Invasive mucinous adenocarcinoma is a unique histologic subtype of lung cancer, and ou...
With the development of technologies, multiple primary lung cancer (MPLC) has been detected more fre...
Summary: Lung adenocarcinoma (LUAD) patients in East Asia predominantly harbor oncogenic EGFR mutati...
With the development of technologies, multiple primary lung cancer (MPLC) has been detected more fre...
Pulmonary invasive mucinous adenocarcinoma (IMA) is considered a variant of lung adenocarcinomas bas...
Background/Aims: Recurrent gene mutation has been identified by the analysis of exonic DNA from lung...
Invasive mucinous adenocarcinoma (IMA) of the lung frequently presents with diffuse pneumonic-type f...
EGFR-mutant lung adenocarcinomas (LUAD) display diverse clinical trajectories and are characterized ...
Background: Lung adenocarcinoma (LUAD) is the most common histologic subtype of lung cancer and has ...
PURPOSE: To better understand the complete genomic architecture of lung adenocarcinoma. EXPERIMENTAL...